The Pacific Northwest (PNW) Prostate Cancer SPORE continuation grant represents a coordinated effort of four institutions with established programs and strengths in translational prostate cancer research including basic, clinical, and population sciences as well as career development: 1) the Fred Hutchinson Cancer Research Center (FHCRC);2) the University of Washington (UW) and its affiliated institutions;3) the University of British Columbia and the Prostate Centre of Vancouver General Hospital (UBC);and 4) Oregon Health and Science University (OHSU). These Seattle-, British Columbia- and Portland-based institutions have large multidisciplinary teams of investigators and laboratories dedicated to prostate cancer research and a history of working closely together within this larger milieu. The respective teams of clinicians and researchers at these institutions bring considerable scientific depth, breadth, creativity, and vision required for confronting the most challenging problems blocking progress in our ultimate goal of reducing the morbidity and mortality associated with prostate cancer. This SPORE proposal enlarges the blueprint for a well-built, distinctive and coordinated translational prostate cancer research effort spanning the entire PNW. All participating institutions have made substantial commitments toward supporting the SPORE and its innovative, translational projects: 1) Molecular predictors of prostate cancer progression and mortality;2) Targeting LSD1 in prostate cancer;3) Targeting SEMA3C in castration resistant prostate cancer;4) Clinical development of therapeutic strategies targeting damage responses in the prostate tumor microenvironment;and 5) Exploiting mechanisms of response and resistance to next generation androgen pathway antagonists. We also propose four Cores to support these projects: 1) Leadership and administration;2) Biospecimens;3) Biostatistics;and 4) Clinical research. In addition, we propose a Developmental Research Program and a Career Development Program that will significantly embellish and strengthen the translational goals of our prostate cancer research program and expand opportunities for engaging young as well as established investigators in our multidisciplinary environment.

Public Health Relevance

Prostate cancer (PC) is a major cause of cancer incidence and mortality in US men. This year alone 240,890 men will be diagnosed and 33,720 will die of the disease;and the annual number of men dying from PC is increasing. This highlights the urgent need for translational PC research to uncover the underlying genetic and genomic factors and pathways that drive PC toward its lethal phenotype, including resistance to therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097186-11A1
Application #
8548562
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
2002-09-19
Project End
2018-08-31
Budget Start
2013-09-17
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$2,150,500
Indirect Cost
$506,168
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Zhang, Ailin; Zhang, Jiawei; Plymate, Stephen et al. (2016) Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression. Horm Cancer 7:104-13
Uo, T; Dvinge, H; Sprenger, C C et al. (2016) Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Oncogene :
Faltermeier, Claire M; Drake, Justin M; Clark, Peter M et al. (2016) Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A 113:E172-81
Lam, Hung-Ming; McMullin, Ryan; Nguyen, Holly et al. (2016) Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts. Clin Cancer Res :
Saranchova, Iryna; Han, Jeffrey; Huang, Hui et al. (2016) Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep 6:30555
Qu, Xiaoyu; Jeldres, Claudio; Glaskova, Lena et al. (2016) Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence. J Mol Diagn 18:215-24
Gulati, Roman; Cheng, Heather H; Lange, Paul H et al. (2016) Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev :
Shui, Irene M; Kolb, Suzanne; Hanson, Christi et al. (2016) Trichomonas vaginalis infection and risk of advanced prostate cancer. Prostate 76:620-3
Coleman, Daniel J; Van Hook, Kathryn; King, Carly J et al. (2016) Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 7:40690-40703
Pritchard, Colin C; Mateo, Joaquin; Walsh, Michael F et al. (2016) Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 375:443-53

Showing the most recent 10 out of 323 publications